Twist Bioscience to Present at SynBioBeta 2019
Twist’s presence at the meeting includes:
Tuesday, October 1, 2019, 2:30pm, Bill Peck, Ph.D., Chief Technology Officer and Co-Founder of Twist Bioscienceon DNA data storage
Tuesday, October 1, 2019, 5:30pm, Aaron Sato, Ph.D., Chief Scientific Officer, Twist Biopharma, a division of Twist Bioscienceon biopharma antibody discovery
Wednesday, October 2, 2019, 1:30pm, Emily Leproust, Ph.D., CEO and Co-Founder of Twist Bioscienceon the company
Thursday, October 3, 2019, 12:30pm, Rebecca Nugent, Ph.D., Director of Research and Development, Twist Bioscienceon redesigning the research funnel
- Booth #225 in the Exhibit Hall
“Growth in synthetic biology’s technology, investment, talent, and innovation has continued to skyrocket over the past year, and we are so excited to see this year’s conference, bringing together all the most important players in the industry,” said SynBioBeta founder and CEO
SynBioBeta is the leading community of innovators, investors, engineers, and thinkers who share a passion for using synthetic biology to build a better, more sustainable universe. We create and energize innovation communities to make the impossible possible via unparalleled opportunities for growth, networking, storytelling, and learning.
Through international synthetic biology conferences and events that bring the entire community together throughout the year, we give innovators the opportunity to meet with other bright minds building and shaping the bioeconomy. We showcase cutting-edge synthetic biology research and technologies that are transforming how we feed, fuel, heal, and build the world.
SynBioBeta offers a weekly industry digest, a podcast, a quarterly magazine (coming soon), and educational courses, in addition to providing our world-class industry partners with opportunities for advertising, partnership, trade show exhibition, strategic consultation, and promotion opportunities. For more information, visit www.synbiobeta.com.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products